Proliferation of mesenchymal stem cell trials for COVID-19: risks and recommendations
Smith JA., Abhari RE., Collins G., Carr AJ.
<p>At least 20 clinical trials of mesenchymal stem/stromal cells (MSCs) for the treatment of covid-19 have been registered. We assess the emerging trial registrations and argue that the information gain is likely to be low, while the likelihood of false-positives and over-interpretation is high. The rush to test treatments may come at the expense of research quality.</p>